Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329325 | 1.00 | DRD1 (0.82) | DRD1CYP3A4TDP1AHR | |
| SCHEMBL29351143 | 0.91 | DRD1 (1.00) | DRD1CYP3A4TDP1 | |
| SCHEMBL6953 | 0.91 | DRD1 (1.00) | DRD1CYP3A4TDP1 | |
| SCHEMBL29359136 | 0.91 | DRD1 (1.00) | DRD1CYP3A4TDP1 | |
| SCHEMBL25373924 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| Ammonia Solution, Strong SCHEMBL19127610 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL38656170 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL15209802 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL17743663 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL28990395 | 0.89 | DRD1 (0.97) | DRD1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611878-A | 3-arylamine (acylamino) pyridine oxazoline chiral ligand and preparation and application thereof | 贵州大学 | 2023-01-17 | — | — | CN | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| CN-110023287-A | Pesticidally active heterocyclic derivatives with sulphur containing substituents | 先正达参股股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9884875-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9499568-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| CN-103180326-A | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL | 2013-06-26 | — | — | CN | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8383642-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2518059-A1 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258961-A1 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| EP-2488500-A1 | SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES | Eli Lilly and Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| US-20110092531-A1 | Novel Spiropiperidine Compounds | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011046851-A1 | SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
| US-20110092531-A1 | Novel Spiropiperidine Compounds | REN, SLC5A1, SLC5A2 | DRD1 413/4885CYP3A4 621/4885TDP1 4058/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
| US-20120258961-A1 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE | APP, IAPP, APBA1 | DRD1 1441/4885CYP3A4 917/4885TDP1 1998/4885 |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | DRD1 119/4885CYP3A4 1896/4885TDP1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.